Anti-Human CD45 (Clone T29/33) – Purified in vivo GOLD^TM Functional Grade

The T29/33 clone is used in in vivo mouse studies as a monoclonal antibody that specifically targets the CD45 protein (also known as leukocyte common antigen) on human hematopoietic cells. This antibody has been developed and optimized for in vivo research applications with several key characteristics that make it suitable for mouse studies.

Antibody Characteristics for In Vivo Use

The T29/33 monoclonal antibody is specifically formulated for in vivo applications with low endotoxin levels (less than 1.0 EU/mg), which is crucial for preventing inflammatory responses that could confound experimental results. It has a mouse IgG1 kappa isotype and maintains high purity (?95% monomer by analytical SEC and >95% by SDS-PAGE), ensuring consistent and reliable performance in vivo.

Target Specificity and Function

The T29/33 clone recognizes an epitope on human CD45, a protein tyrosine phosphatase receptor type C (PTPRC) that is expressed on the surface of all nucleated hematopoietic cells. This antibody binds specifically to all human hematopoietic cells, including T-cells, B-cells, and other immune cells, but does not react with non-hematopoietic cells such as erythrocytes, liver, brain, or kidney tissue.

Research Applications

In mouse studies, the T29/33 antibody serves multiple research purposes. It can be used to track and identify human hematopoietic cells in xenograft models, where human immune cells are transplanted into immunocompromised mice. The antibody is particularly valuable for studying immune cell signaling, as CD45 plays a pivotal role in regulating the signaling threshold of lymphocyte activation and differentiation.

Formulation and Administration

The antibody is formulated in phosphate-buffered saline (PBS) at pH 7.2-7.4 without carrier proteins, potassium, calcium, or preservatives, making it suitable for direct in vivo administration. It's available in various sizes ranging from 1 mg to 100 mg, allowing researchers to select appropriate quantities for their specific experimental designs.

Importantly, the T29/33 antibody is noted to be non-cytotoxic in the presence of complement, which means it can be used for cell tracking and identification without causing significant cell death. This characteristic is particularly valuable for longitudinal studies where researchers need to monitor cell populations over time without depleting them through antibody-mediated cytotoxicity.

Based on the available search results, I cannot find specific storage temperature requirements for the sterile packaged clone T29/33. The search results mention clone T29/33 only briefly as an anti-human CD45 antibody clone from Leinco Technologies used in antibody-drug conjugate experiments, but do not provide any storage temperature specifications for this particular product.

The search results do contain storage temperature information for other laboratory materials, but these are not applicable to clone T29/33:

• Universal Transport Medium (UTM) should be stored between 2-25°C
• Fetal bovine serum requires storage at -10°C or lower for long-term storage
• Plant clones can be stored at 35°F (approximately 2°C) for extended periods

To obtain the correct storage temperature for clone T29/33, you would need to consult the product documentation or contact Leinco Technologies directly, as this specific information is not available in the provided search results.

Commonly used antibodies or proteins in the literature alongside T29/33 (an anti-CD45, pan-leukocyte marker) include:

• CD14: Frequently combined in dual-color flow cytometry to distinguish monocytes from other leukocytes when using T29/33 as a general leukocyte marker.
• Other CD45 clones: Such as clone 2D1, also targeting the leukocyte common antigen for cross-validation or comparative purposes.
• CD11c/CD18: Sometimes assessed in parallel to identify different immune cell subsets, especially dendritic cells or myeloid cells, in conjunction with pan-leukocyte gating by T29/33.

In immunohistochemistry and diagnostic workflows analyzing lymphomas or undifferentiated neoplasms, T29/33 (pan-hematopoietic), is typically part of a panel that includes:

• Epithelial markers (such as cytokeratins) to distinguish non-hematopoietic tumors.
• Other hematopoietic lineage markers (e.g., CD3 for T cells, CD20 for B cells) to characterize the type of lymphoid neoplasm.

Additionally, in contexts involving interleukin-33 biology, researchers use ST2 antibodies (IL-33 receptor), and antibodies to related immune signaling proteins, but those are less directly related to the classic diagnostic/flow uses of T29/33.

In summary, the most common pairings with T29/33 in standard immunophenotyping or diagnostic protocols are CD14, other CD45 clones, and markers that discriminate between hematopoietic and non-hematopoietic cells, with additional markers selected based on specific research or diagnostic goals.

Key findings from clone T29/33 citations in scientific literature center on its role as a monoclonal antibody targeting a pan-hematopoietic antigen, chiefly CD45, and its value in tumor diagnostics and immunophenotyping.

• Clone T29/33 as a Diagnostic Tool: Monoclonal antibody T29/33 recognizes a 200,000-dalton pan-hematopoietic glycoprotein antigen, most likely CD45, which is broadly expressed on hematopoietic cells. Studies show it is positive in nearly all hematopoietic tumors examined (~200 cases), with rare exceptions (e.g., some plasmacytomas), and largely negative in non-hematopoietic tumors such as undifferentiated carcinomas or sarcomas. Its reactivity profile makes it a valuable instrument for differentiating lymphomas from non-lymphoid tumors, especially undifferentiated malignant neoplasms that are difficult to classify based solely on histopathology.

• Specificity and Limitations: While generally reliable, a minority of plasmacytomas (3 of 6 tested) did not react with T29/33, and one sarcoma was positive, indicating rare false-negatives and positives. This must be considered in differential diagnosis.

• Use in Immunophenotyping: T29/33 is routinely used in flow cytometry panels for labeling CD45 across various studies involving lymphocyte subpopulations in peripheral blood. It is paired with other monoclonal antibodies specific to CD4, CD8, CD14, and additional markers, enabling detailed immunophenotypic analysis.

• Technical Details and Considerations: Experimental protocols using clone T29/33 involve direct and indirect immunofluorescence or immunoenzyme techniques for tissue sections and blood samples. Commercial sources of the antibody are documented, and controls (isotype-matched and secondary reagents) are employed to ensure specificity.

In summary, clone T29/33 is a reliable pan-hematopoietic antibody (for CD45) widely cited for its utility in distinguishing hematopoietic from non-hematopoietic neoplasms, with proven utility in diagnostic immunohistochemistry and flow cytometry, though rare exceptions in specific tumor types are documented.